Does Medicare Advantage Cover Zepbound? 2026 Rules for MA-PD, Sleep Apnea, Weight Loss, and the $50 Bridge
Published:
·Last verified: May 20, 2026.·Sources: CMS.gov, Medicare.gov, FDA/DailyMed, Eli Lilly, KFFThe answer in plain English:
Yes — but only when your plan includes prescription drug coverage and the prescription matches one of two routes. If Zepbound is prescribed for moderate-to-severe obstructive sleep apnea in an adult with obesity, your MA-PD plan may cover it through Part D, usually with prior authorization. If it’s prescribed for weight loss, the new path is the Medicare GLP-1 Bridge — a CMS demonstration starting July 1, 2026, priced at a flat $50/month for Zepbound KwikPen only.
Your Medicare Advantage Zepbound Coverage Route Matrix — May 2026
Here’s the fast version of where you land. The rest of this guide walks you through each row.
| Your situation | Your route | Who processes | Counts toward $2,100 cap? | What you’d pay |
|---|---|---|---|---|
| MA plan with no drug coverage (MA-only) | No Zepbound route through your MA plan | n/a | n/a | Cash-pay only |
| MA-PD + moderate-to-severe OSA + obesity | Part D formulary or formulary exception | Your plan's PBM | Yes | Plan-specific copay (often $47–$95 Tier 3; 25–33% coinsurance Tier 4) |
| MA-PD + weight loss (before July 1, 2026) | Not standard Part D — prepare for Bridge or cash-pay | n/a | n/a | $50 Bridge isn't open yet |
| MA-PD + weight loss (July 1, 2026 or later) | Medicare GLP-1 Bridge | Humana (CMS-designated central processor) | No | $50/month for Zepbound KwikPen only |
| Denied a Zepbound PA | Decode the denial, then appeal or re-submit | Your plan's PBM (OSA) or Humana (Bridge) | Depends on route | Cost unresolved until decision |
| Medicare route won't work for you | FDA-approved cash-pay backup | n/a | No | $299–$449/month through Lilly's Self Pay Journey (KwikPen, terms apply) |
Sources: CMS Medicare GLP-1 Bridge FAQ (last modified May 12, 2026), FDA/DailyMed Zepbound prescribing information, Medicare.gov 2026 Part D cost rules, Eli Lilly Self Pay Journey terms. Verified May 20, 2026.
Find your exact route in 60 seconds
Five quick questions and you’ll know which Medicare Advantage path applies, what to ask your plan, and what your doctor needs to submit.
Take the Free GLP-1 Path Quiz →Why this question is so confusing in the first place
A 22-year-old federal law and a 2024 FDA approval are pulling Medicare Advantage in opposite directions. Here’s the short story so the rest of this guide makes sense.
The 2003 rule
Medicare's prescription drug law (the Medicare Modernization Act) blocks Part D from covering drugs used for weight loss or weight gain. That hasn't changed.
The December 2024 unlock
The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. OSA isn't weight loss, so it sidesteps the 2003 exclusion. Medicare Advantage plans with Part D coverage can list Zepbound on formulary for that use.
The December 2025 unlock
CMS announced the BALANCE Model and the Medicare GLP-1 Bridge. The Bridge starts July 1, 2026 and runs through December 31, 2027 — the first time eligible Medicare Part D beneficiaries can access GLP-1 drugs through a CMS pathway for weight management, for $50 a month, outside the Part D benefit.
The April 2026 wrinkle
CMS confirmed that not enough Part D plans signed up for the broader BALANCE Model in 2027, so BALANCE is on hold for Medicare. The Bridge was extended through the end of 2027 instead.
Timeline at a glance
| Date | What happened |
|---|---|
| December 2024 | FDA approves Zepbound for moderate-to-severe OSA in adults with obesity |
| December 23, 2025 | CMS announces the BALANCE Model and the Medicare GLP-1 Bridge |
| March 3, 2026 | CMS releases Bridge eligibility and operational FAQ |
| April 6, 2026 | CMS clarifies the Bridge includes Foundayo (all formulations), Wegovy (injection and tablets, all formulations), and Zepbound KwikPen only |
| April 30, 2026 | CMS confirms BALANCE will not launch for Medicare Part D in 2027 — 80% plan-participation threshold wasn't met |
| May 12, 2026 | CMS Bridge page last updated |
| July 1, 2026 | Medicare GLP-1 Bridge begins |
| December 31, 2027 | Medicare GLP-1 Bridge currently scheduled to end |
Does Medicare Advantage cover Zepbound? The 3 questions that decide your route
Don’t ask “does Medicare Advantage cover Zepbound” as a yes-or-no question. Ask these three instead.
1Does your Medicare Advantage plan include Part D drug coverage?
Medicare Advantage comes in two flavors:
MA-PD plan
Medicare Advantage with prescription drug coverage built in. Most Medicare Advantage enrollees have this. This is the plan type that can access both routes.
MA-only plan
Medicare Advantage without prescription drug coverage. Common for veterans (VA pharmacy) and some PPO buyers who use a separate drug plan or pay cash. No Zepbound pharmacy route through this plan.
Zepbound is a self-administered weekly injection — that puts it on the drug side of your plan (Part D), not the medical side (Part B). Medicare.gov is clear: Part B covers drugs not typically self-administered; Part D covers the rest. Zepbound is “the rest.”
2What is the prescription actually for?
This is the question almost no one asks before calling their plan — and it decides everything.
Prescribed for: Moderate-to-severe OSA + obesity
Part D formulary or formulary exception, with prior authorization. This is not the Bridge.
Prescribed for: Weight loss / chronic weight management
Regular Part D will not cover this. The only Medicare route for weight management is the Medicare GLP-1 Bridge starting July 1, 2026 — with its own eligibility rules.
Prescribed for: Submitted as weight loss when patient also has OSA
Your MA-PD plan will reject it under the weight-loss exclusion. Same drug, same patient, different label, totally different coverage outcome.
3Which formulation of Zepbound is prescribed?
Almost zero competing pages mention this — and it can be the difference between $50/month and a full-price denial under the Bridge.
| Formulation | In Bridge? | OSA route coverage? |
|---|---|---|
| Zepbound KwikPen (multi-dose) | ✅ Yes — only formulation in the Bridge | Yes (confirm tier with plan) |
| Zepbound single-dose pen | ❌ Not in the Bridge | May be covered; confirm NDC |
| Zepbound single-dose vial | ❌ Not in the Bridge | May be covered; confirm NDC |
Does Medicare Advantage cover Zepbound for sleep apnea?
What you need to qualify for the OSA route
A confirmed diagnosis of moderate-to-severe obstructive sleep apnea, typically from an in-lab sleep study (polysomnography) or a qualifying home sleep apnea test (HSAT)
Obesity, as defined by the Zepbound FDA label — typically BMI ≥ 30
Enrollment in Medicare Part D, either as an MA-PD plan or a standalone Part D plan on top of Original Medicare
Your specific MA-PD plan's formulary lists Zepbound for the OSA indication, or your prescriber successfully requests a formulary exception
A prior authorization packet from your doctor that includes the sleep study, the obesity documentation, and a prescription that specifies OSA — not weight loss
What to say when you call your MA-PD plan
Copy-paste this. Read it word-for-word. The exact phrasing matters because the indication is what unlocks coverage.
Write down the rep’s name, the date, the time, the reference number, and every answer. You may need that paper trail later if there’s a denial.
A small but important detail about wording
If your doctor writes the prescription as “Zepbound for weight loss” — even if you also have sleep apnea — your MA-PD plan will reject it under the weight-loss exclusion. Same drug, same patient, different label, totally different coverage outcome. Make sure your doctor’s chart note and prescription both state the OSA indication. This is the single most common fixable mistake we see.
Does Medicare Advantage cover Zepbound for weight loss?
Before July 1, 2026
- ·Check whether the OSA route applies (do you also have moderate-to-severe sleep apnea?)
- ·Prepare your Bridge documentation now so you’re ready on day one
- ·Use a cash-pay FDA-approved path if you don’t want to wait
Standard Part D will not cover weight-loss-only Zepbound during this window.
On or after July 1, 2026 (Bridge)
- ·Prescription must be for Zepbound KwikPen specifically
- ·Doctor submits PA to Bridge central processor (Humana), not your plan’s PBM
- ·You pay $50/month at the pharmacy counter
- ·That $50 does not count toward your $2,100 Part D OOP cap
- ·Single-dose vials and single-dose pens not covered by the Bridge
What is the Medicare GLP-1 Bridge, and does it include Zepbound?
How the Bridge actually operates
CMS designed the Bridge to bypass the Part D weight-loss exclusion by running outside the Part D benefit entirely.
PA submission
Your provider submits the prior authorization to the Medicare GLP-1 Bridge central processor — which CMS has designated as Humana, the current LI NET administrator. The PA does not go to your MA-PD plan's normal PBM.
Pharmacy claim routing
Your pharmacy processes the claim under the Bridge's dedicated BIN/PCN: 028918 / MEDDGLP1BR. If your pharmacy can't find this routing, ask them to look up the Medicare GLP-1 Bridge specifically.
Your cost
You pay $50 at the counter. CMS reimburses the pharmacy at no lower than the drug's wholesale acquisition cost minus your copay, plus a dispensing fee.
Manufacturer rebate
The manufacturer rebates CMS for the difference between the wholesale price and the negotiated $245/month net price.
Part D separation
None of this touches your Part D benefit. The $50 does not count toward your deductible or your $2,100 out-of-pocket cap.
Bridge eligibility criteria
CMS sets the rules. Your plan doesn’t get to add extra hoops — but you must meet all of these:
Age
18 or older
Plan enrollment
Enrolled in a qualifying Part D plan — standalone PDP or eligible MA-PD plan type
Prescription purpose
Written for weight reduction and ongoing weight maintenance, paired with structured nutrition and physical activity
Drug formulation
Must be Zepbound KwikPen specifically (eligible NDC required)
Plus one of three BMI routes:
BMI ≥ 35
At the time you started GLP-1 therapy. No additional diagnosis needed.
BMI 30–34.9
Plus at least one of: heart failure with preserved ejection fraction (HFpEF), uncontrolled high blood pressure on two BP medications (systolic >140 or diastolic >90 mmHg), or chronic kidney disease stage 3a or higher.
BMI 27–29.9
Plus at least one of: prediabetes (per ADA criteria), prior heart attack, prior stroke, or symptomatic peripheral artery disease.
Practical notes:
- ·The BMI threshold is judged at the time you started GLP-1 therapy, not your current BMI. If you began with BMI 37 and are now at 32, your prescriber can attest you met the BMI ≥ 35 criterion at initiation.
- ·Pregnant or breastfeeding individuals are not eligible.
- ·Your prescriber cannot be on the CMS Preclusion List.
The exact Zepbound NDCs covered by the Bridge
CMS publishes the specific National Drug Codes that qualify. As of the May 12, 2026 update, these are the Zepbound KwikPen NDCs included in the Bridge:
CMS says this list may be updated during the Bridge. If you or your pharmacist need to verify an NDC at the counter, confirm against the current CMS Medicare GLP-1 Bridge page. Foundayo and Wegovy have their own NDC lists.
Which Medicare Advantage plan types qualify for the $50 Bridge?
The Bridge is nationwide, but not every Medicare Advantage plan type is eligible.
✅ Plan types that qualify
| Plan type |
|---|
| MA-PD HMO (Health Maintenance Organization) |
| MA-PD HMO-POS (HMO with point-of-service flexibility) |
| MA-PD local PPO (Preferred Provider Organization) |
| MA-PD regional PPO |
| Special Needs Plans (SNPs) — D-SNP, C-SNP, I-SNP |
| Employer/Union Group Waiver Plans (EGWPs) |
| Limited Income Newly Eligible Transition (LI NET) participants |
❌ Plan types that don’t qualify
| Plan type |
|---|
| Medicare Advantage Private Fee-for-Service (PFFS) plans |
| Section 1876 cost contract plans |
| Section 1833 health care prepayment plans |
| PACE (Programs of All-Inclusive Care for the Elderly) |
| Fallback plans |
| Religious fraternal benefit plans |
You can still get into the Bridge if you also enroll in a standalone Part D plan, where that’s possible for your situation.
One critical caveat for Extra Help / Low-Income Subsidy beneficiaries
If you qualify for Extra Help (the Low-Income Subsidy, or LIS), LIS subsidies do not apply to the Bridge’s $50 monthly copay. The $50 also doesn’t count toward your Part D true out-of-pocket spending (TrOOP), which means it doesn’t push you any closer to the $2,100 catastrophic-coverage threshold for your other covered Part D drugs. For someone on Extra Help who normally pays the LIS copay for covered drugs, $50 may actually feel expensive. Knowing this in advance matters.
How to check your specific MA-PD formulary for Zepbound
Plan formularies change. The fastest, most accurate way to know what your plan covers is to check the formulary yourself, then call your plan and confirm.
Step 1 — Find your plan's drug formulary
Log into your plan's member portal (look for a drug list, formulary, or "find a drug" search tool), or use the Medicare.gov Plan Finder and search your plan's covered drugs list. Eli Lilly's coverage checker at zepbound.lilly.com is a useful starting point, but Lilly notes it's not a guarantee — confirm with your insurer.
Step 2 — Search for both "Zepbound" and "tirzepatide"
Some formularies list brand name, some list active ingredient, some list both. Cover your bases. Note which indications the listing covers (some plans flag OSA specifically; others list the drug without specifying use).
Step 3 — Note the four things that decide cost and access
Coverage tier (typically Tier 3 or Tier 4 specialty for brand-name GLP-1s), prior authorization required (almost always yes), step therapy required (some plans require CPAP trial for OSA, or other GLP-1 attempts for weight management), and quantity limits (most plans cap at one pen or one box per 28–30 days).
Step 4 — Call the number on your member ID card
Use the call script from the OSA section above. Get the rep's answers in writing if possible. If they're vague or give conflicting info, ask for a supervisor.
Step 5 — Get your doctor's office on the same page
Email your doctor's office with: the exact indication you want on the prescription, the formulation needed (KwikPen if routing through the Bridge), the documentation your plan's PA form requires, and the fax or portal where the PA needs to go.
Get the call script + PA checklist for your route
Same 60-second quiz, but this time you walk away with the exact phrasing to use with your plan and your doctor.
Find Your GLP-1 Path →What your doctor actually needs to submit for the prior authorization
The PA packet looks different depending on which route you’re using. Mixing the two up is the most common cause of denials we see.
OSA route — PA packet contents
- ✓Prescription written specifically for moderate-to-severe obstructive sleep apnea in an adult with obesity
- ✓Copy of sleep study (polysomnography or qualifying HSAT) showing AHI score consistent with moderate-to-severe OSA
- ✓Current BMI documentation (typically ≥ 30)
- ✓Letter of medical necessity tying the OSA diagnosis to the FDA-approved Zepbound OSA indication
- ✓Documentation of any CPAP trial — whether tolerated, declined, or contraindicated
- ✓The specific Zepbound NDC and dose strength being prescribed
- ✓Prescriber's NPI and signature
Bridge route — PA packet contents
PA goes to Medicare GLP-1 Bridge central processor (Humana), not your plan’s normal PBM.
- ✓Prescription for Zepbound KwikPen specifically, with an eligible NDC (see NDC list above)
- ✓Attestation that the drug is for weight reduction and ongoing weight maintenance with structured nutrition and physical activity
- ✓BMI documentation at the time of GLP-1 therapy initiation
- ✓Documentation of any qualifying comorbidity if BMI is below 35 (HFpEF, uncontrolled HTN on 2 BP meds, CKD stage 3a+, prediabetes, prior MI, prior stroke, or symptomatic PAD)
- ✓Prescriber's confirmation they are not on the CMS Preclusion List
- ✓Pharmacy routes claim through Bridge BIN/PCN: 028918 / MEDDGLP1BR
Copy-paste message to send your doctor’s office
“Can your office confirm whether my Zepbound prescription should go through my MA-PD plan for the OSA indication, or through the Medicare GLP-1 Bridge for weight management? I want to make sure the PA includes the right diagnosis, the right formulation (KwikPen if Bridge), my BMI at GLP-1 initiation, and the supporting documentation the route needs. Could we confirm which route fits my situation before submitting?”
This 90-second message prevents the most common cause of Medicare GLP-1 denials: the PA submitted under the wrong route.
The honest catch: why the $50 Bridge headline doesn’t mean what most people think
The $50 Bridge headline is real. It’s also surrounded by qualifiers.
The $50 a month does not mean every Medicare Advantage member walks into a pharmacy on July 1 and gets any version of Zepbound for $50. It means eligible MA-PD members get Zepbound KwikPen specifically, if they meet the BMI and comorbidity criteria, if their plan type qualifies, if the prior authorization is approved by the CMS central processor, and they understand the $50 doesn’t count toward their Part D out-of-pocket protection.
Eligible plan types only: PFFS, PACE, and a handful of other plan types are out unless you have a standalone PDP.
KwikPen only: Single-dose pens and vials don't qualify under the Bridge.
BMI/comorbidity gate: BMI ≥ 35 alone, or BMI ≥ 30 with one of three conditions, or BMI ≥ 27 with one of four conditions.
Outside Part D flow: Your $50 copays don't move you closer to the $2,100 annual cap that protects you on other prescription drugs.
No subsidies stack on top: LIS / Extra Help cost-sharing reductions don't apply to the $50.
The genuine reframe:
Even with every qualifier, $50/month is roughly 83% to 89% less than Lilly’s current self-pay tiers ($299–$449), and far less than full retail cash prices that can clear $1,000. The Bridge isn’t perfect. But for someone who meets the criteria and has a KwikPen prescription, it’s the cleanest Medicare route to Zepbound for weight management that’s ever existed.
How much will Zepbound actually cost you on Medicare Advantage in 2026?
Your real cost depends entirely on which route applies to you.
| Coverage route | Typical 2026 cost | Counts toward $2,100 cap? |
|---|---|---|
| MA-PD + OSA on formulary (Tier 3) | Often $47–$95/month after deductible | Yes |
| MA-PD + OSA on formulary (Tier 4 specialty) | Often 25–33% of plan price | Yes |
| MA-PD + OSA via formulary exception | Same as the granted tier if approved | Yes |
| Medicare GLP-1 Bridge (July 2026+) | Flat $50/month for Zepbound KwikPen only | No |
| Lilly Self Pay Journey — 2.5 mg | $299/month (offer terms apply) | No |
| Lilly Self Pay Journey — 5 mg | $399/month (offer terms apply) | No |
| Lilly Self Pay Journey — 7.5, 10, 12.5, 15 mg | $449/month (45-day refill rule applies) | No |
| Retail pharmacy cash (no offer) | Often $900+/month at major chains | No |
2026 Part D deductible
Plans can charge up to $615 before benefits kick in. Many MA-PD plans charge less or none.
2026 Part D OOP cap
$2,100 for covered drugs. Once you hit it, your covered Part D drugs cost $0 for the rest of the calendar year.
Extra Help / LIS (Part D covered drugs)
Can reduce 2026 copays to up to $5.10 for generics and $12.65 for brand-name drugs. People with full Medicaid and QMB status may pay less. LIS does not reduce the Bridge $50.
The cap protects OSA route, not Bridge
The $2,100 annual cap applies to OSA-route coverage. The Bridge $50 is separate and does not count.
A practical example
You’re on an MA-PD plan. You have moderate OSA + obesity. Your plan lists Zepbound on Tier 3 with a $90 copay after a $215 deductible. You’d pay:
- ·Month 1: $215 (deductible) + $90 copay portion above deductible = roughly $215–$305 depending on how the plan applies the deductible
- ·Months 2 onward: $90/month until you hit $2,100 OOP
- ·After cap: $0 for covered drugs for the rest of the calendar year
What about Lilly coupons, GoodRx, and savings cards on Medicare Advantage?
GoodRx and similar discount cards
Cash-pay programs only. They aren't insurance claims and don't count toward your Part D out-of-pocket cap. You can use them — but only as a cash-pay backup, not in combination with your MA-PD plan.
Manufacturer savings cards
Lilly's terms exclude government program enrollees. If you were paying $25/month on commercial insurance and switched to Medicare Advantage, the savings card does not carry over.
Double-dipping is prohibited
You can't combine the Bridge $50 and a Lilly savings card. CMS prohibits stacking.
What to do if your Medicare Advantage plan denies Zepbound
The denial reason decoder
| What the denial letter says | What it usually means | Your next action |
|---|---|---|
| "Weight loss drugs are excluded" | PA submitted as weight loss, not OSA | If you have OSA, confirm the diagnosis is in your chart and ask the doctor to resubmit with the OSA indication |
| "Drug is not on formulary" | Plan doesn't list Zepbound for the indication you requested | Request a formulary exception with supporting documentation |
| "Prior authorization required" or "PA criteria not met" | PA was missing, incomplete, or didn't meet the plan's clinical criteria | Submit a complete PA with the full documentation packet |
| "Not medically necessary" | Plan's clinician reviewer didn't see enough evidence | Get the plan's specific criteria, address each one in writing, include your sleep study and BMI history |
| "Step therapy required" | Plan wants you to try CPAP, a lower-tier drug, or another option first | Ask your doctor about a step-therapy exception if there's a clinical reason CPAP/alternatives aren't appropriate |
| "Wrong formulation" or "Not eligible under the Bridge" | Prescription was for a vial or single-dose pen | Get a new prescription specifically for Zepbound KwikPen |
The Medicare Advantage appeals path
Level 1 — Plan Redetermination
Standard Part D drug redetermination deadlines apply; expedited requests have faster timelines. Check your specific denial letter for the exact deadline — it's required to be in writing.
Level 2 — Independent Review Entity (IRE) reconsideration
If Level 1 fails, an independent contractor reviews the decision.
Level 3 — Administrative Law Judge hearing
Available if the amount in controversy meets a threshold.
Level 4 — Medicare Appeals Council
The next level if Level 3 is unsuccessful.
Level 5 — Federal District Court judicial review
The final formal review level. Most cases are resolved at Level 1 or Level 2.
What a strong Zepbound OSA appeal includes
- ✓Sleep study results with the AHI (Apnea-Hypopnea Index) score showing moderate-to-severe OSA
- ✓Current BMI documentation
- ✓A clinician letter of medical necessity that explicitly cites Zepbound's FDA-approved OSA indication
- ✓Documentation of any prior CPAP trial (success, failure, or contraindication)
- ✓A citation to the Zepbound prescribing information confirming OSA approval
Ask your doctor’s office if they have a template — many do. If they don’t, ask whether the office’s billing or appeals staff can help.
Decode your denial in 60 seconds
Tell us the denial reason and we’ll route you to the exact next step — corrected PA, formulary exception, appeal, or Bridge route.
Find Your GLP-1 Path →Switching Medicare Advantage plans for Zepbound coverage
Medicare Advantage enrollees get two annual windows to change plans. Either one can be used to move to a plan that covers Zepbound for the indication you need.
Annual Enrollment Period (AEP)
October 15 – December 7
You can switch from any MA plan to another MA plan, drop MA and go back to Original Medicare, change your Part D plan, or do nothing. Changes take effect January 1.
MA Open Enrollment Period (MAOEP)
January 1 – March 31
If you're already in an MA plan on January 1, you can make one additional change: switch to a different MA plan or drop MA and return to Original Medicare. You cannot use MAOEP to enroll in MA for the first time.
How to compare plans for Zepbound coverage
Premiums are not the first thing to look at. Formulary placement is. Here’s the order that actually matters:
| Priority | What to check |
|---|---|
| 1 — First | Is Zepbound on the plan's formulary? Search for tirzepatide/Zepbound. |
| 2 | For what indication? OSA, Bridge eligibility, or both? |
| 3 | What tier? Tier 3 vs Tier 4 specialty can change your annual cost by thousands. |
| 4 | What's the deductible? Up to $615 in 2026. |
| 5 — Last | What's the premium? Factor this in only after the formulary analysis. |
| Also | Provider network — make sure your prescriber and pharmacy are in-network. |
| Also | Prior auth and step therapy requirements — published in the plan's formulary documents. |
Use Medicare.gov Plan Finder — it is the official tool and the most current data source. Your State Health Insurance Assistance Program (SHIP) offers free Medicare counseling to help interpret what you find.
If Medicare Advantage won’t cover Zepbound: your FDA-approved cash-pay backup
No Medicare claim
You don't get the $2,100 Part D out-of-pocket protection or Bridge pricing. You're paying out of pocket.
No double-dipping
Lilly's terms exclude government program enrollees from the savings card. CMS prohibits coupon stacking with the Bridge.
FDA-approved only
This section covers FDA-approved Zepbound at cash-pay prices — not compounded tirzepatide, which is outside the scope of this guide.
Direct from Eli Lilly: the Self Pay Journey
Lilly’s Self Pay Journey is the manufacturer’s direct-to-consumer self-pay program. As of May 20, 2026, Lilly’s published pricing for Zepbound KwikPen:
Zepbound KwikPen 2.5 mg
$299/month
Zepbound KwikPen 5 mg
$399/month
Zepbound KwikPen 7.5, 10, 12.5, 15 mg
$449/month
The $449 tier requires completing each refill within 45 days of your prior delivery or receipt date. Miss that window and Lilly’s regular prices apply. Lilly defines a month as 28 days. Taxes, fees, and offer terms apply. You can use a prescription from your existing prescriber.
Telehealth as a structured cash-pay path
Some Medicare beneficiaries don’t have an existing prescriber comfortable with GLP-1 medications, or want a more guided experience. A telehealth provider can fill that gap — but only as a cash-pay path. It is not a Medicare coverage route.
Ro — FDA-approved cash-pay path
For Medicare beneficiaries who’ve confirmed their Medicare route is closed
What Ro offers
- ✓Carries FDA-approved Zepbound (and Foundayo) — not compounded substitutes
- ✓$39 for the first month, then $149/month for Ro Body, or as low as $74/month with annual prepay
- ✓Zepbound KwikPen cash-pay: $299/mo (2.5 mg), $399/mo (5 mg), $449/mo (7.5–15 mg) with manufacturer offer
- ✓Free GLP-1 Insurance Coverage Checker — useful even if you’re filing the Medicare PA through your own doctor
Important limitations
- ✗Ro cannot coordinate GLP-1 coverage for government insurance plans
- ✗If you have Medicaid or another government-funded plan, Ro says you cannot join Ro Body
- ✗Medication cost is separate from the membership fee
- ✗Ro does not make Medicare pay for Zepbound — it is strictly a cash-pay path
Get started for $39, then as low as $74/month for Ro Body with annual prepay (medication priced separately). This is a cash-pay option, not Medicare coverage. Use it only after confirming your Medicare route is closed. Affiliate disclosure.
If telehealth isn’t right for you, the Self Pay Journey through your existing doctor’s prescription is the simpler path. Either works.
Who shouldn’t use Zepbound (regardless of coverage)
Coverage is not the same as clinical fit. According to the FDA-approved Zepbound label, Zepbound is contraindicated in patients with:
- !A personal or family history of medullary thyroid carcinoma
- !Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- !Serious hypersensitivity to tirzepatide or any other ingredient in Zepbound
There are also warnings around pancreatitis, gallbladder disease, hypoglycemia in patients also taking insulin or sulfonylureas, kidney injury, severe gastrointestinal disease, and diabetic retinopathy. The full safety information is in the FDA-approved Zepbound prescribing information. This is not medical advice — always discuss clinical appropriateness with your doctor before pursuing coverage.
What we actually verified for this guide
We re-verify this page monthly because the underlying rules are still moving. Last verified: May 20, 2026.
| Claim verified | Source | Last verified |
|---|---|---|
| Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 | CMS.gov Medicare GLP-1 Bridge page | May 20, 2026 |
| Bridge includes Foundayo (all formulations), Wegovy (injection + tablets), Zepbound KwikPen only | CMS.gov Medicare GLP-1 Bridge FAQ | May 20, 2026 |
| Zepbound KwikPen NDCs: 0002-3566-11, 0002-3555-11, 0002-3544-11, 0002-3533-11, 0002-3522-11, 0002-3511-11 | CMS.gov Medicare GLP-1 Bridge page | May 20, 2026 |
| Bridge central processor is Humana; BIN/PCN 028918 / MEDDGLP1BR | CMS.gov Medicare GLP-1 Bridge FAQ | May 20, 2026 |
| Bridge BMI/comorbidity criteria (≥35 alone; ≥30 with HFpEF/HTN/CKD 3a+; ≥27 with prediabetes/MI/stroke/PAD) | CMS.gov Medicare GLP-1 Bridge FAQ | May 20, 2026 |
| Bridge $50 copay does not count toward Part D OOP cap; LIS does not apply to Bridge copay | CMS.gov Medicare GLP-1 Bridge FAQ | May 20, 2026 |
| Zepbound FDA-approved for moderate-to-severe OSA in adults with obesity (Dec 2024) | FDA / DailyMed Zepbound prescribing information | May 20, 2026 |
| 2026 Part D max deductible $615; OOP cap $2,100 | Medicare.gov Part D costs page | May 20, 2026 |
| 2026 Extra Help copays up to $5.10 (generic) / $12.65 (brand) at participating pharmacies | Medicare.gov Help with drug costs page | May 20, 2026 |
| Lilly Zepbound Savings Card excludes Medicare/Medicaid/TRICARE enrollees | zepbound.lilly.com card terms | May 20, 2026 |
| Lilly Self Pay Journey: $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg); 45-day refill rule applies to $449 tier | zepbound.lilly.com / Lilly Self Pay Journey terms | May 20, 2026 |
| Ro pricing ($39 first month, $149/mo or $74/mo annual prepay); $299/$399/$449 KwikPen | ro.co/weight-loss/pricing | May 20, 2026 |
| KFF: 80.7% of appealed MA prior authorization denials overturned in 2024; 11.5% of denied requests appealed | KFF analysis of CMS Medicare Advantage data | May 20, 2026 |
| BALANCE Model not launching in Medicare Part D for 2027 | KFF analysis + CMS confirmation, April 2026 | May 20, 2026 |
What we did not verify in this guide:
- ·Your specific MA-PD plan's current formulary placement of Zepbound
- ·Your prescriber's willingness to submit either route's PA
- ·Pharmacy inventory or local availability of Zepbound KwikPen
- ·Your final out-of-pocket cost after your plan adjudicates the claim
Always confirm coverage and cost with your plan before filling a prescription.
Frequently Asked Questions
Does Medicare Advantage cover Zepbound?
Medicare Advantage can cover Zepbound only when your plan includes prescription drug coverage (an MA-PD plan) and the prescription matches one of two routes: Part D coverage for moderate-to-severe obstructive sleep apnea in adults with obesity, or the Medicare GLP-1 Bridge for weight management starting July 1, 2026.
Does Medicare Advantage cover Zepbound for sleep apnea?
Yes, an MA-PD plan can cover Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity — the FDA-approved sleep apnea indication. Coverage depends on your plan's formulary listing it for that use, and almost always requires prior authorization with sleep study documentation.
Does Medicare Advantage cover Zepbound for weight loss?
Not through ordinary Part D — federal law still excludes weight-loss drugs from Part D coverage. But starting July 1, 2026, eligible MA-PD members can access Zepbound KwikPen through the Medicare GLP-1 Bridge for $50 per month if they meet BMI and clinical criteria.
Does the $50 Medicare price apply to every version of Zepbound?
No. CMS includes only the Zepbound KwikPen formulation in the Medicare GLP-1 Bridge. The single-dose vial and single-dose pen formulations are not covered under the Bridge.
Does the $50 Bridge copay count toward my Part D out-of-pocket limit?
No. The Bridge operates outside the standard Part D benefit. The $50 copay does not count toward the 2026 Part D out-of-pocket cap of $2,100.
Can I use Extra Help (LIS) with the $50 Bridge copay?
No. Low-income cost-sharing subsidies do not apply to the Bridge copay. They continue to apply to your other covered Part D drugs, where 2026 Extra Help copays can be up to $5.10 for generics and up to $12.65 for brand-name drugs.
Can I use the Lilly Zepbound Savings Card with Medicare Advantage?
No. Lilly's Zepbound Savings Card explicitly excludes anyone enrolled in Medicare, Medicare Part D, Medicare Advantage, Medigap, Medicaid, VA, DoD, or TRICARE.
What if my doctor prescribed Zepbound for both OSA and weight loss?
The use submitted to the plan is what matters. If your prescriber submits the prior authorization for the OSA indication, you go the Part D route. If they submit it for weight management on or after July 1, 2026, the Bridge applies assuming you meet the criteria. CMS has stated that a drug already coverable under standard Part D like Zepbound for OSA is not eligible for Bridge coverage instead.
Which Medicare Advantage plans cover Zepbound?
There is no trustworthy national list — coverage depends on your ZIP code, plan year, MA-PD status, formulary, diagnosis, and whether you are using the OSA or Bridge route. Use the Medicare.gov Plan Finder to search your specific plan's 2026 formulary, then call the number on your member ID card to confirm prior authorization rules, tier, and step therapy.
Does Original Medicare cover Zepbound?
Original Medicare Parts A and B do not directly cover Zepbound. Zepbound is a self-administered weekly injection, which falls under Part D, not Part B. If you have Original Medicare and want Zepbound coverage, you typically need a standalone Part D plan. The same OSA and Bridge rules apply.
Can a telehealth provider submit the prior authorization?
For the Bridge specifically, CMS has said a prescriber doesn't need to be enrolled in Medicare to submit a prior authorization — but they must not be on the CMS Preclusion List. For the OSA Part D route, your prescriber needs to be a properly credentialed clinician licensed to prescribe Zepbound in your state and recognized by your plan.
What if I'm under 65 on Medicare due to disability?
The same rules apply. Bridge eligibility doesn't have a separate age rule beyond 18 or older. If you're enrolled in an eligible Part D plan and meet the BMI and comorbidity criteria, you can use the Bridge regardless of how you became Medicare-eligible.
Will my MA-PD plan keep covering Zepbound after the Bridge ends in 2027?
This is genuinely uncertain. CMS originally planned to roll the Bridge into a longer-term BALANCE Model for Part D starting in 2027, but the 80% Part D plan participation threshold wasn't met, and BALANCE is on hold for Medicare. The Bridge has been extended through December 31, 2027. We update this page when CMS clarifies the post-Bridge picture.
Does Medicare Advantage cover Mounjaro for the same things as Zepbound?
Mounjaro and Zepbound contain the same active ingredient (tirzepatide), but they're FDA-approved for different uses. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and moderate-to-severe OSA. Your MA-PD plan may cover Mounjaro for type 2 diabetes when on formulary. It is not interchangeable with Zepbound for FDA-approved purposes.
Does Medicare Advantage cover compounded tirzepatide?
This guide is about FDA-approved Zepbound. Compounded tirzepatide is a different regulatory category, and Medicare Advantage plans don't cover it as a Zepbound coverage route. That path is outside the scope of this guide.
Sources
- ·1. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. Last modified May 12, 2026. cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- ·2. Centers for Medicare & Medicaid Services. BALANCE Model. cms.gov/priorities/innovation/innovation-models/balance
- ·3. U.S. Food and Drug Administration / DailyMed. Zepbound (tirzepatide) Prescribing Information.
- ·4. Medicare.gov. Costs for Medicare drug coverage. medicare.gov/health-drug-plans/part-d/basics/costs
- ·5. Medicare.gov. Help with drug costs. medicare.gov/basics/costs/help/drug-costs
- ·6. Medicare.gov. How Medicare drug plans work. medicare.gov/health-drug-plans/part-d/what-drug-plans-cover/how-drug-plans-work
- ·7. Eli Lilly and Company. Zepbound Coverage & Savings. zepbound.lilly.com/access-coverage
- ·8. Eli Lilly and Company. Zepbound HCP Coverage & Savings — Self Pay Journey terms. zepbound.lilly.com/hcp/coverage-savings
- ·9. KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. April 2026.
- ·10. KFF. Nearly 50 Million Prior Authorization Requests Were Sent to Medicare Advantage Insurers in 2023 (and 2024 update). kff.org
- ·11. Reed Smith LLP. CMS Provides Details for "Medicare GLP-1 Bridge" Coverage for Eligible Part D Beneficiaries. March 2026.
- ·12. Ro. Zepbound and Medicare for Sleep Apnea. ro.co/weight-loss/does-medicare-cover-zepbound-sleep-apnea
- ·13. Ro. Insurance Coverage for GLP-1 Medications. ro.co/weight-loss/insurance
- ·14. Ro. Weight Loss Pricing. ro.co/weight-loss/pricing
Still mapping out your route?
The fastest way to get a personalized answer is our free quiz. Five questions. Personalized action plan based on your plan type, diagnosis, BMI, and current coverage status. No signup required.
The Ro link is a cash-pay option, not Medicare coverage. Only use it after confirming your Medicare route is closed.
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. This page is informational and does not constitute medical, insurance, or legal advice. Always confirm coverage and clinical appropriateness with your Medicare Advantage plan and a licensed healthcare provider before making medication decisions.
Published:
· Last verified: May 20, 2026. Next scheduled review: June 20, 2026.Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.